tiprankstipranks
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
US Market
Holding ACRV?
Track your performance easily

Acrivon Therapeutics, Inc. (ACRV) Income Statement

158 Followers

Acrivon Therapeutics, Inc. Income Statement

Last quarter (Q3 2024), Acrivon Therapeutics, Inc.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Acrivon Therapeutics, Inc.'s net income was $-22.44M. See Acrivon Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
-$ 134.00K$ 537.00K$ 0.00$ 0.00
Cost of Revenue
-----
Gross Profit
-$ 134.00K$ 537.00K--
Operating Expense
$ 94.93M$ 67.10M$ 32.66M$ 16.18M$ 3.17M
Operating Income
$ -85.30M$ -67.10M$ -32.66M$ -16.18M$ -3.17M
Net Non Operating Interest Income Expense
$ 13.84M$ 7.00M$ 1.50M--
Other Income Expense
$ 11.95M$ 6.71M$ 1.49M$ -59.00K$ -2.14M
Pretax Income
$ -81.98M$ -60.39M$ -31.17M$ -16.24M$ -5.31M
Tax Provision
-----
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -76.98M$ -60.39M$ -31.17M$ -16.24M$ -5.31M
Basic EPS
$ -2.71$ -2.74$ -7.56$ -1.26$ -0.41
Diluted EPS
$ -2.71$ -2.74$ -7.56$ -1.26$ -0.41
Basic Average Shares
$ 119.17M$ 22.08M$ 4.12M$ 12.88M$ 12.88M
Diluted Average Shares
$ 119.17M$ 22.08M$ 4.12M$ 12.88M$ 12.88M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 85.30M$ 67.10M$ 32.66M$ 16.18M$ 3.17M
Net Income From Continuing And Discontinued Operation
$ -76.98M$ -60.39M$ -31.17M$ -16.24M$ -5.31M
Normalized Income
$ -56.05M$ -47.72M-$ -16.24M$ -5.31M
Interest Expense
-----
EBIT
$ -79.96M$ -67.10M$ -32.66M$ -16.18M$ -3.17M
EBITDA
$ -78.51M$ -66.57M$ -32.29M$ -16.15M$ -3.15M
Currency in USD

Acrivon Therapeutics, Inc. Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis